Analyst Reco. Infinity Pharmaceuticals, Inc.

Equities

INFI.Q

US45665G3039

End-of-day quote OTC Markets Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-99.96%

Mar. 25	North American Morning Briefing : Tech in Focus on -2-	DJ
Mar. 25	Infinity Pharmaceuticals, Inc. Went Out of Business	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Stocks Futures Steady on Rates Optimism	Nov. 20	DJ
Piper Sandler Downgrades Infinity Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $0.30 From $3	23-02-24	MT
B. Riley Downgrades Infinity Pharmaceuticals to Neutral From Buy, Lowers PT to $1.50 From $3; Moves to Sidelines Until Partner Helps Advance Eganelisib	22-11-15	MT
JonesTrading Downgrades Infinity Pharmaceuticals to Hold From Buy	22-08-15	MT
B. Riley Lowers Infinity Pharmaceuticals' Price Target to $3 from $5 to Reflect Delay in Eganelisib's Development, Uncertainty on Timing of Partnership; Maintains Buy Rating	22-08-10	MT
Piper Sandler Adjusts Infinity Pharmaceuticals' Price Target to $3 from $4, Keeps Overweight Rating	22-05-23	MT
Truist Adjusts Infinity Pharmaceuticals' Price Target to $4 from $12, Keeps Buy Rating	22-03-31	MT
Oppenheimer Adjusts Infinity Pharmaceuticals Price Target to $7 From $9, Maintains Outperform Rating	22-03-30	MT
Piper Sandler Adjusts Infinity Pharmaceuticals' Price Target to $4 From $8, Reiterates Overweight Rating	22-03-30	MT
B. Riley Lowers Infinity Pharmaceuticals' Price Target to $5 from $7 After Revising Cost Capital Assumptions, Keeps Buy Rating	22-01-24	MT
B. Riley Lifts Infinity Pharmaceuticals' PT to $7 from $4 Following MARIO-3 Results in Frontline Metastatic Triple-Negative Breast Cancer, Keeps Buy Rating	21-12-16	MT
INFINITY PHARMACEUTICALS : HC Wainwright Starts Infinity Pharmaceuticals at Buy With $9 Price Target	21-10-18	MT
ANALYST RECOMMENDATIONS : ConvaTec, DiscoverIE, LKQ, Unite Group, WidomTree...	21-08-02
INFINITY PHARMACEUTICALS : JPMorgan Upgrades Infinity Pharmaceuticals to Overweight From Neutral; Price Target is $6	21-08-02	MT
INFINITY PHARMACEUTICALS : B. Riley Lowers Infinity Pharmaceuticals' PT to $4 from $7 on Mixed Results, Uncertainty on Regulatory Path in Metastatic Urothelial Cancer; Keeps Buy Rating	21-07-28	MT
INFINITY PHARMACEUTICALS : Piper Sandler Adjusts Infinity Pharmaceuticals' Price Target to $8 From $7, Maintains Overweight Rating	21-07-28	MT
INFINITY PHARMACEUTICALS : Wells Fargo Lifts Infinity Pharmaceuticals to Overweight From Equal-Weight, Price Target to $14 From $4	21-07-28	MT
ANALYST RECOMMENDATIONS : Flutter, Hasbro, MGM Resort, Microsoft Vodafone...	21-07-28
INFINITY PHARMACEUTICALS : Truist Securities Starts Infinity Pharmaceuticals at Buy With $12 Price Target	21-03-18	MT
INFINITY PHARMACEUTICALS : Wells Fargo Adjusts Infinity Pharmaceuticals' Price Target to $4 from $2, Keeps Equalweight Rating	21-03-17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Infinity Pharmaceuticals, Inc.

Equities

INFI.Q

US45665G3039

Analyst Reco.

Filters